The expression of KIF2A in GC is upregulated when compared to that in normal gastric tissue, and this overexpression is associated with lymph node metastasis, advanced TNM stages, and a poor prognosis; therefore, we suggest that KIF2A could be a prognostic marker, even a molecular target, in GC therapy. Here, KIF2A is linked to gastric cancer.